5-year follow-up of the phase III AUGMENT trial in 358 patients with relapsed/refractory indolent NHL: lenalidomide plus rituximab vs rituximab plus placebo improved PFS (HR 0.50) and, as a secondary end point, OS (HR 0.59) at median 65.9 months.
RCTn = 358
Leonard et al. Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial